The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback